title: Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
abstract: OBJECTIVE
  This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BCl2; p53; and angiogenesis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis.
  
  
  RESULTS
  The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as an independent predictive factor for survival. Bcl2-positive tumors showed a better time to recurrence (P = .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pT1N0, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously.
  
  
  CONCLUSIONS
  Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.
authors.affiliation: Department of Thoracic Surgery, Royal Brompton Hospital, London, United Kingdom. u.pastorino@rbh.nthames.nhs.uk
authors.forename: U
authors.initials: U
authors.lastname: Pastorino
authors.forename: S
authors.initials: S
authors.lastname: Andreola
authors.forename: E
authors.initials: E
authors.lastname: Tagliabue
authors.forename: F
authors.initials: F
authors.lastname: Pezzella
authors.forename: M
authors.initials: M
authors.lastname: Incarbone
authors.forename: G
authors.initials: G
authors.lastname: Sozzi
authors.forename: M
authors.initials: M
authors.lastname: Buyse
authors.forename: S
authors.initials: S
authors.lastname: Menard
authors.forename: M
authors.initials: M
authors.lastname: Pierotti
authors.forename: F
authors.initials: F
authors.lastname: Rilke
mesh_terms: D000017:ABO Blood-Group System; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D017474:Receptors, Laminin / Q000032:analysis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D000017:ABO Blood-Group System; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D019253:Proto-Oncogene Proteins c-bcl-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D017474:Receptors, Laminin; D016159:Tumor Suppressor Protein p53